Van Bockstal et al. (2020) discovered that HER2 gene amplification had a relationship with a bad result in invasive breast cancer and the amplification of heterogeneous HER2 had been described in 5–41% of breast cancer. This evidence concerns the gene ERBB2 and breast cancer.